User profiles for JONG SEOK LEE

Jong-Seok Lee

Professor at Yonsei University
Verified email at yonsei.ac.kr
Cited by 9978

NTIRE 2021 challenge on image deblurring

…, S Son, S Lee, R Timofte, KM Lee… - Proceedings of the …, 2021 - openaccess.thecvf.com
Motion blur is a common photography artifact in dynamic environments that typically comes
jointly with the other types of degradation. This paper reviews the NTIRE 2021 Challenge on …

Aim 2020 challenge on efficient super-resolution: Methods and results

…, Y Qu, GW Jeon, JH Choi, JH Kim, JS Lee… - Computer Vision–ECCV …, 2020 - Springer
This paper reviews the AIM 2020 challenge on efficient single image super-resolution with
focus on the proposed solutions and results. The challenge task was to super-resolve an …

[HTML][HTML] Pembrolizumab for the treatment of non–small-cell lung cancer

…, E Carcereny, MJ Ahn, E Felip, JS Lee… - … England Journal of …, 2015 - Mass Medical Soc
Background We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition
with pembrolizumab in patients with advanced non–small-cell lung cancer enrolled in a …

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

…, OA Frontera, F De Marinis, H Turna, JS Lee… - The Lancet, 2017 - thelancet.com
Background Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1)
monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 …

Deap: A database for emotion analysis; using physiological signals

…, C Muhl, M Soleymani, JS Lee… - IEEE transactions on …, 2011 - ieeexplore.ieee.org
We present a multimodal data set for the analysis of human affective states. The
electroencephalogram (EEG) and peripheral physiological signals of 32 participants were recorded …

[HTML][HTML] Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden

…, TE Ciuleanu, A Pluzanski, JS Lee… - … England Journal of …, 2018 - Mass Medical Soc
Background Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–small-cell
lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has …

[HTML][HTML] Recent advances in the synthesis of 2-pyrones

JS Lee - Marine Drugs, 2015 - mdpi.com
Jong Seok Lee … Very recently, Lee and co-workers successfully applied a gold(I)-catalyzed
2-pyrone synthesis to the total synthesis of (+)-violapyrone C (Scheme 15) [33]. … Shin, HJ; …

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

…, I Kirgner, CY Kuo, MC Lazaroiu, K Le Du, JS Lee… - The Lancet, 2019 - thelancet.com
Background Based on the encouraging activity and manageable safety profile observed in
a phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of …

Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node …

…, SS Seo, S Lee, JY Kim, SK Kim, KW Kang, JS Lee… - Cancer, 2006 - Wiley Online Library
BACKGROUND The objective of the current study was to determine the accuracy of magnetic
resonance imaging (MRI) and positron emission tomography/computed tomography (PET/…

[HTML][HTML] Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS …

…, S Viteri, JY Han, SW Kim, CK Lee… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Non–small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)
exon 20 insertion (Exon20ins) mutations exhibits inherent resistance to approved …